CCR5 and COVID-19: As this patient is an N=1 case, it is interesting to note the severe, nearly lethal phenotype of this patient and to be CCR5 delta 32 homozygous, suggesting that CCR5 complete inhibition does not remove HLH risks as others have proposed for COVID-19 (91).